TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03861910

Intervention type: DIETARY_SUPPLEMENT
Intervention: hypoallergenic formulas
Description: hypoallergenic formulas used for cow milk allergy treatment

Intervention type: DIETARY_SUPPLEMENT
Intervention: hypoallergenic formulas
Description: hypoallergenic formulas used for cow milk allergy treatment

Intervention type: DIETARY_SUPPLEMENT
Intervention: hypoallergenic formulas
Description: hypoallergenic formulas used for cow milk allergy treatment

Intervention type: DIETARY_SUPPLEMENT
Intervention: hypoallergenic formulas
Description: hypoallergenic formulas used for cow milk allergy treatment

Intervention type: DIETARY_SUPPLEMENT
Intervention: hypoallergenic formulas
Description: hypoallergenic formulas used for cow milk allergy treatment
Study: NCT04807465

Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in etch&rinse mode
Description: The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.

Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in etch&rinse mode
Description: The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.

Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in selective-etch mode
Description: The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.

Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in selective-etch mode
Description: The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.

Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in self-etch mode
Description: The adhesive system was applied to the enamel and dentin surfaces.

Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in self-etch mode
Description: The adhesive system was applied to the enamel and dentin surfaces.
Study: NCT00936442

Intervention type: DRUG
Intervention: Anastrozole
Description: (Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.

Intervention type: DRUG
Intervention: Anastrozole
Description: (Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.

Intervention type: OTHER
Intervention: Educational materials
Description: Reception of educational material on regular basis.
Study: NCT02062047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PMSRP
Description: Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
Study: NCT01265355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-rotavirus protein
Description: 11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin 1 gm daily
Study: NCT04697277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section
Study: NCT03634124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Additional blood test of 4,5 ml of venous blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Vascular ultrasonic vascular exploration of the lower limbs
Study: NCT04451122

Intervention type: OTHER
Group type: OTHER
Intervention: cleansing the eyelid margins
Description: using eyelid cleaning wipes to cleansing the eyelid margins
Study: NCT04503525

Intervention type: OTHER
Intervention: Nutritional assessment
Description: Nutritional assessment in COVID patients
Study: NCT01353222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DN24-02
Description: DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Observation only until documentation of disease recurrence.
Study: NCT04794231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing
Description: a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 \[8.5 x 10.5cm\] or 1633 \[7 × 8.5 cm\] depending on patient size; 3M, Neuss, Germany)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate -impregnated dressing group
Description: A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R \[7 x 8.5 cm\] or \[11.5 x 8.5 cm\] depending on patient size; 3M, Neuss, Germany).
Study: NCT02062047

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application and irrigation of placebo, rinsing placebo solution during 60 days
Study: NCT00653458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ODT, 8 mg, single-dose, fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: ODT, 8 mg, single-dose, under fed conditions
Study: NCT00542880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide Diskus (salmeterol/fluticasone) 50/500 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide Diskus (salmeterol/fluticasone) 50/500 μg
Study: NCT01269879

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexi-Bar vibration device only
Description: daily vibration training 10min twice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexi-Bar + XCO-Trainer
Description: XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group
Study: NCT00696384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Description: Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
Study: NCT01547897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOX-E36
Description: 0.5 mg/kg study drug or placebo as SC injections twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOX-E36
Description: 0.5 mg/kg study drug or placebo as SC injections twice a week
Study: NCT02027402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with drain insertion
Description: In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
Study: NCT03958084

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
Study: NCT04457557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced concentration of local anesthetic (ropivacaine)
Description: Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual concentration of local anesthetic (ropivacaine)
Description: 0.5% ropivacaine 15ml
Study: NCT01949779

Intervention type: DEVICE
Intervention: TransForm™ Occlusion Balloon Catheter
Description: TransForm™ Occlusion Balloon Catheter
Study: NCT02154984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Follow tRD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive coaching calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02813070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: PET brain imaging and Magnetic resonance brain imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: PET brain imaging and Magnetic resonance brain imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: PET brain imaging and Magnetic resonance brain imaging
Study: NCT04179721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PES-4-BPSD Model
Description: Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The attention control condition
Description: Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training).
Study: NCT04099043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cascade Continuous Glucose Monitoring System
Description: Continuous Glucose Monitoring for 15 days
Study: NCT01593202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: 16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
Study: NCT02036957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BALM ARM
Description: The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO ARM
Description: The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
Study: NCT02232308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Study: NCT04295005

Intervention type: DRUG
Intervention: Empagliflozin
Description: film coated tablet
Study: NCT02404012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Description: Participants will be provided supplementation for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron supplementation
Description: Participants will be provided supplementation for 8 weeks
Study: NCT03199261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rE-4 Injection
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rE-4 Freeze-dried Powder
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
Study: NCT04295005

Intervention type: DRUG
Intervention: DPP-4i
Description: film coated tablets, specifically Sitagliptin

Intervention type: DRUG
Intervention: GLP-1-RA
Description: subcutaneous injection or tablet
Study: NCT03826290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-integrated diabetes dashboard
Description: The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
Study: NCT00692094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
Study: NCT04152902

Intervention type: OTHER
Intervention: Objective outcome
Description: The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis

Intervention type: OTHER
Intervention: Objective outcome
Description: The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis

Intervention type: OTHER
Intervention: Quality of life
Description: SF-36 Questionnaire

Intervention type: OTHER
Intervention: Quality of life
Description: SF-36 Questionnaire
Study: NCT02142647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a high-protein complementary diet with meat
Description: infants will consume a high-protein complementary diet with protein mainly from meat

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a high-protein complementary diet with dairy
Description: infants will consume a high-protein complementary diet with protein mainly from dairy
Study: NCT02052310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
Study: NCT02773550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Low dose of bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT03217448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
Study: NCT02219893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOC31PE Immunotoxin
Description: Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
Study: NCT03866941

Intervention type: BEHAVIORAL
Intervention: causes of abuse synthetic cannibinoids
Description: Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
Study: NCT02657616

Intervention type: DRUG
Intervention: vitamin-k-antagonists

Intervention type: DRUG
Intervention: Novel oral anticoagulants
Study: NCT04356833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1
Description: Patients in the cohort 1 rt-PA group will receive the first dose as soon as possible after registration. 10mg rt-PA in 5mL diluent will be administered by nebulisation every 6 hours for 14 days, resulting in a total daily dose of 40mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV
Description: Patients on IMV will receive 60mg daily over three doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV
Description: NIV patients will receive 60mg daily for over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
Study: NCT03688984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia
Description: Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.